Screener
Eikon Therapeutics, Inc. EIKN Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $70,047 | $56,587 |
| General and administrative | 17,290 | 14,796 |
| Total operating expenses | 87,337 | 71,383 |
| Loss from operations | (87,337) | (71,383) |
| Interest income (expense), net | 4,380 | 3,160 |
| Other income (expense), net | (1) | (20) |
| Net loss and comprehensive loss | (82,958) | (68,243) |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s total operating expenses?
- Eikon Therapeutics, Inc. (EIKN) reported total operating expenses of $87.34M in Q1 2026.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Eikon Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude